

**Date and Time:** Friday 15<sup>th</sup> March 2013, 10:00-13:00

**Minutes:**

***Lipid Modification Guideline***

**Guideline Development Group Meeting 5**

**Place:** Meeting via teleconference and Web-Ex

<b>GDG Present:</b>	Anthony Wierzbicki (Chair)	(Present for notes 1 – 4)
	Rajai Ahmad	(Present for notes 1 – 4)
	Lindsay Banks	(Present for notes 1 – 4)
	Liz Clark	(Present for notes 1 – 4)
	Eleanor Grey	(Present for notes 1 – 4)
	Michael Khan	(Present for notes 1 – 4)
	Emma McGowan	(Present for notes 1 – 4)
	Dermot Neely	(Present for notes 1 – 4)
	Nadeem Qureshi	(Present for notes 1 – 4)
	Alan Rees	(Present for notes 1 – 4)
<b>NCGC Present:</b>	Martin Harker	(Present for notes 1 – 4)
	Norma O’Flynn	(Present for notes 1 – 4)
	Silvia Rabar	(Present for notes 1 – 4)

**In attendance:**

NICE Staff:		
-------------	--	--

**Observers:**

--	--	--

**Agenda item**

1. **Welcome introductions and apologies**  
Anthony Wierzbicki welcomed the group to the fifth meeting of this GDG and thanked them for their time and commitment to the guideline. Apologies were received from David Wald, Martin Duerden, Maggie Westby, David Wonderling, Lina Gulhane, Angela Cooper and Clifford Middleton.

2. **Declaration of Interests**  
The Chair asked all GDG members to declare any new relevant conflicts of interest. The group then verbally declared the following new DOIs:

Michael Khan:  
- Personal pecuniary interest: I gave a talk at Expo on FH; this was sponsored by an educational grant to the Organising committee by AstraZeneca.

3. **Review Question: For adults without established CVD (primary prevention) and with established CVD (secondary prevention) what is the clinical and cost**

## **Agenda item**

### **effectiveness of statin therapy? Head-to head comparison of different intensity statins**

The Chair introduced Silvia Rabar (Senior Project Manager and Research Fellow at NCGC) who gave a presentation on the clinical and cost effectiveness of different doses of statin therapy for the prevention of cardio-vascular disease, and took questions from the group. The GDG then discussed the evidence and discussed the strategy for further analysis. The Chair thanked Silvia Rabar for her presentation.

#### **4. Summary of next steps and any other business**

There were no other businesses to discuss. The Chair closed the meeting and thanked everybody for attending.

### **Date, time and venue of the next meeting**

Wednesday 24<sup>th</sup> April 2013, at NCGC.